Skip to main
ARGX
ARGX logo

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 54%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has demonstrated significant financial growth, achieving $761.2 million in total revenue for 4Q24, which represents an 82.2% increase year-over-year, exceeding both internal estimates and street consensus. The company's positive trajectory is underscored by breakeven operating profit in 3Q24, with expectations for improving operating margins due to increasing sales and stabilizing R&D expenditures. Additionally, Argenx is committed to innovation, as evidenced by its robust pipeline and healthy R&D spending strategy, which positions it well for continued growth and expansion in the biopharmaceutical market.

Bears say

Argenx reported a year-over-year decline in R&D expenses of 3.0%, totaling $297.2 million in 4Q23, which, while above estimates, indicates potential challenges in effective resource allocation and prioritization amidst a competitive landscape. The company faces several significant risks that could adversely impact future growth, including lower-than-anticipated sales growth for Vyvgart, the emergence of new competitors, and potential setbacks in ongoing trials for key therapies. Additionally, there is heightened concern regarding competitive pressures and macroeconomic factors that may negatively influence the company's pipeline and overall financial performance.

argenx (ARGX) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 54% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 28 analysts, argenx (ARGX) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $602.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $602.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.